Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial)

<p>Abstract</p> <p>Background</p> <p>The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin<sup>® </sup>ES) administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated peritoneal di...

Full description

Bibliographic Details
Main Authors: Isbel Nicole M, Campbell Scott B, Hawley Carmel M, Brown Fiona, Leary Diana, Noble Euan, Barraclough Katherine A, Mudge David W, van Eps Carolyn L, Sturtevant Joanna M, Johnson David W
Format: Article
Language:English
Published: BMC 2009-07-01
Series:BMC Nephrology
Online Access:http://www.biomedcentral.com/1471-2369/10/20

Internet

http://www.biomedcentral.com/1471-2369/10/20

Similar Items